sacituzumab,trastuzumab deruxtecan
gilead sciences,Daiichi Sankyo,AstraZeneca
['breast', 'vance', 'trodelvy', 'enhertu', 'gilead']
survival data with ' trodelvy in advanced hr+, her2- #breastcancer exceeds expectations, sparking debate over its role versus enhertu in this setting #esmo22 
https://t.co/O0ZJQGuINh, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate